Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors
- PMID: 31600806
- DOI: 10.1055/s-0039-1695769
Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors
Conflict of interest statement
P.W. reports receiving grant support, lecture fees, and advisory board fees from Bayer HealthCare, lecture fees from Medscape, Pfizer, and Daiichi Sankyo, fees for serving on a writing committee from Itreas, grant support from Bristol-Myers Squibb/Pfizer, consulting fees from Janssen Scientific, and fees for serving on a roundtable from Sanofi. M.C. reports receiving grant support and honoraria from Leo Pharma and Bayer and honoraria from Sanofi-Aventis, Pfizer, and Bristol-Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical